-
MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-118 CLINICAL STUDY: New PPARg covalent partial agonist in healthy volunteers
Read more: MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-118 CLINICAL STUDY: New PPARg covalent partial agonist in healthy volunteersNavarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase…
-
Medibiofarma participated in the “Startup Spotlight” event of the annual BIO-Europe Spring conference held on March 26, 2019 in Vienna, Austria
Read more: Medibiofarma participated in the “Startup Spotlight” event of the annual BIO-Europe Spring conference held on March 26, 2019 in Vienna, AustriaMedibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of Medibiofarma,…
-
Medibiofarma announces the completion of a new financing round
Read more: Medibiofarma announces the completion of a new financing roundMedibiofarma announces the completion of a new financing round of 2 million euros, with the financial support of its founder team and the incorporation of new partners, among them, Sodena,…
-
Medibiofarma announces the nomination of a second Development Candidate
Read more: Medibiofarma announces the nomination of a second Development CandidateCompound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
-
Medibiofarma announced the nomination of a new Development Candidate
Read more: Medibiofarma announced the nomination of a new Development CandidateCompound MBF-118, a novel PPAR-γ receptor modulator for the treatment of cancer. The compound will start IND enabling studies the second quarter 2018.
